Wednesday, July 8, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

CEP-1347 10mg

Phase 3 · small molecule · Parkinson Disease

CEP-1347 10mg for Parkinson Disease is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All Teva Pharma GmbH projects Phase 3 small molecule terminated

Internal code C1347c/204/PD/US-CA

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Phase 3
Modality
small_molecule
Indication
Parkinson Disease
Status
terminated
Trials
1